Ava closes seed round of $2.6 million
The Swiss women’s health startup Ava has successfully closed a seed round of USD 2.6M
Renowned institutional investors and business angels invest USD 2.6 million in Ava. This large seed-round underlines the company’s ambition to become a relevant player in women’s health.
Bracelet for smart baby planning
Ava empowers couples who are trying to get pregnant by giving them precise insights about the
menstrual cycle. Ava has developed a sensor bracelet for women to be worn at night. Based on 3 million
data points measured every night, the Ava bracelet offers key cycle health information and precisely
predicts fertile days and ovulation in advance. 80% of pregnancies happen within this two day fertile
window. Ava thus helps couples maximize their chances to conceive and gives them certainty along their
exciting journey. The company has won several innovation prices for its technology, and was selected by
TechCrunch Disrupt San Francisco among the world’s most promising tech companies.
The seed round was raised from institutional investors and business angels. ZKB and Swisscom – two of
the most renowned Swiss early stage investors – will invest in Ava. An international group of scientists,
gynecologists, entrepreneurs, and executives will join as business angels. Among them are Yonca Even
Guggenbühl (co-founder MediService) and Dr. Valentin Chapero (former CEO Sonova).
“The interest in our financing round was very high – we could have raised twice as much”, says Pascal
Koenig, co-founder and CEO of Ava. “The money will be used to accelerate industrialization of the
technology and to bring the product to market. The trust from investors is a great motivation for our
team to realize our vision and make a difference in women’s health.”
In context with the financing round, Ava will strengthen its board of directors. Dr. Ruedi Gygax, former
Managing Director of Novartis Venture Fund, will bring in his expertise in scaling innovation companies
in the healthcare space. Renate Schreiber, former CEO of Medela, will bring in her expertise and global
network in women’s health. “Two things were crucial for me to get involved at Ava. First, the fact that
the product can make a true difference in many people’s lives. Second, Ava’s team, which is composed
of a group of smart, complementary, and highly committed people”, explains Renate Schreiber.
Together with the University Hospital of Zurich, Ava has built up a database of six billion data points
referenced to hormonal measurements. This is the largest such database in the world. While the
company will focus on the conceiving market at the beginning, the patented technology can also be
used to detect pathologies during pregnancy, and for non-hormonal contraception. Ava is currently
building up an office in San Francisco to prepare market entry which is planned mid-2016. Earlybird
subscriptions are accepted on www.avawomen.com.